Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
Public ClinicalTrials.gov record NCT03207256. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Extension Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination With Other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
Study identification
- NCT ID
- NCT03207256
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 9, 2017 (Actual)
- Primary completion
- May 25, 2022 (Actual)
- Completion
- Jun 24, 2022 (Actual)
- Last update posted
- Jul 21, 2022
2017 – 2022
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | Huntsville | Alabama | 35805 | — |
| TG Therapeutics Investigational Trial Site | Tucson | Arizona | 85711 | — |
| TG Therapeutics Investigational Trial Site | Fayetteville | Arkansas | 72703 | — |
| TG Therapeutics Investigational Trial Site | Duarte | California | 91010 | — |
| TG Therapeutics Investigational Trial Site | Fort Myers | Florida | 33901 | — |
| TG Therapeutics Investigational Trial Site | Atlanta | Georgia | 30322 | — |
| TG Therapeutics Investigational Trial Site | Fort Wayne | Indiana | 46804 | — |
| TG Therapeutics Investigational Trial Site | Coon Rapids | Minnesota | 55433 | — |
| TG Therapeutics Investigational Trial Site | Omaha | Nebraska | 68198 | — |
| TG Therapeutics Investigational Trial Site | Durham | North Carolina | 27710 | — |
| TG Therapeutics Investigational Site | Canton | Ohio | 44718 | — |
| TG Therapeutics Investigational Trial Site | Cincinnati | Ohio | 45242 | — |
| TG Therapeutics Investigational Trial Site | Nashville | Tennessee | 37203 | — |
| TG Therapeutics Investigational Trial Site | Denton | Texas | 76210 | — |
| TG Therapeutics Investigational Trial Site | San Antonio | Texas | 78229 | — |
| TG Therapeutics Investigational Trial Site | Seattle | Washington | 98104 | — |
| TG Therapeutics Investigational Trial Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03207256, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2022 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03207256 live on ClinicalTrials.gov.